Skip to content

Study · Randomized controlled trial · n = 76 · 2020

12 results

Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes.

Liu L, Yan H, Xia M, Zhao L, Lv M, Zhao N, Rao S, Yao X, Wu W, Pan B, Bian H, Gao X

Diabetes/metabolism research and reviews10 Feb 2020Cited by 100 (Europe PMC)

PMID31955491 (opens in a new tab)DOI10.1002/dmrr.3292 (opens in a new tab)PepBankPUB-31955491
Publisher pagePubMedAsk about this study
Jump to 12 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

11 results from studies that gave the peptide. 11 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes and fatty liver disease, exenatide reduced ALT more than insulin glargine.

    In plain wordsIn patients with diabetes and fatty liver disease, exenatide reduced ALT more than insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseAlanine transaminase
    Study

    n = 76

    Comparator
    Insulin glargine
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Moreover, exenatide treatment resulted in greater reductions in alanine transaminase (ALT), aspartate transaminase (AST), and gamma glutamyl transpeptidase (GGT) than insulin glargine (P < 0.05).
    3 context sentences
    Summary · context
    The aim of this study was to investigate the efficacy of exenatide and insulin glargine in patients with newly diagnosed type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD).
    Summary · context
    We performed a 24-week randomized controlled multicentre clinical trial.
    Summary · context
    Seventy-six patients were randomly assigned 1:1 to receive exenatide or insulin glargine treatment.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes and fatty liver disease, exenatide reduced AST more than insulin glargine.

    In plain wordsIn patients with diabetes and fatty liver disease, exenatide reduced AST more than insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseAspartate transaminase
    Study

    n = 76

    Comparator
    Insulin glargine
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Moreover, exenatide treatment resulted in greater reductions in alanine transaminase (ALT), aspartate transaminase (AST), and gamma glutamyl transpeptidase (GGT) than insulin glargine (P < 0.05).
    3 context sentences
    Summary · context
    The aim of this study was to investigate the efficacy of exenatide and insulin glargine in patients with newly diagnosed type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD).
    Summary · context
    We performed a 24-week randomized controlled multicentre clinical trial.
    Summary · context
    Seventy-six patients were randomly assigned 1:1 to receive exenatide or insulin glargine treatment.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes and fatty liver disease, exenatide reduced GGT more than insulin glargine.

    In plain wordsIn patients with diabetes and fatty liver disease, exenatide reduced GGT more than insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseGamma glutamyl transpeptidase
    Study

    n = 76

    Comparator
    Insulin glargine
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Moreover, exenatide treatment resulted in greater reductions in alanine transaminase (ALT), aspartate transaminase (AST), and gamma glutamyl transpeptidase (GGT) than insulin glargine (P < 0.05).
    3 context sentences
    Summary · context
    The aim of this study was to investigate the efficacy of exenatide and insulin glargine in patients with newly diagnosed type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD).
    Summary · context
    We performed a 24-week randomized controlled multicentre clinical trial.
    Summary · context
    Seventy-six patients were randomly assigned 1:1 to receive exenatide or insulin glargine treatment.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes and fatty liver disease, exenatide reduced body weight more than insulin glargine.

    In plain wordsIn patients with diabetes and fatty liver disease, exenatide reduced body weight more than insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBody weight
    Study

    n = 76

    Comparator
    Insulin glargine
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    The body weight, waist circumference, postprandial plasma glucose, and low-density lipoprotein cholesterol (LDL-C) in the exenatide group also presented greater reductions than the insulin glargine group (P < .05).
    3 context sentences
    Summary · context
    The aim of this study was to investigate the efficacy of exenatide and insulin glargine in patients with newly diagnosed type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD).
    Summary · context
    We performed a 24-week randomized controlled multicentre clinical trial.
    Summary · context
    Seventy-six patients were randomly assigned 1:1 to receive exenatide or insulin glargine treatment.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes and fatty liver disease, exenatide reduced waist circumference more than insulin glargine.

    In plain wordsIn patients with diabetes and fatty liver disease, exenatide reduced waist circumference more than insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseWaist circumference
    Study

    n = 76

    Comparator
    Insulin glargine
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    The body weight, waist circumference, postprandial plasma glucose, and low-density lipoprotein cholesterol (LDL-C) in the exenatide group also presented greater reductions than the insulin glargine group (P < .05).
    3 context sentences
    Summary · context
    The aim of this study was to investigate the efficacy of exenatide and insulin glargine in patients with newly diagnosed type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD).
    Summary · context
    We performed a 24-week randomized controlled multicentre clinical trial.
    Summary · context
    Seventy-six patients were randomly assigned 1:1 to receive exenatide or insulin glargine treatment.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes and fatty liver disease, exenatide reduced postprandial glucose more than insulin glargine.

    In plain wordsIn patients with diabetes and fatty liver disease, exenatide reduced blood sugar after meals more than insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePostprandial plasma glucose
    Study

    n = 76

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    The body weight, waist circumference, postprandial plasma glucose, and low-density lipoprotein cholesterol (LDL-C) in the exenatide group also presented greater reductions than the insulin glargine group (P < .05).
    3 context sentences
    Summary · context
    The aim of this study was to investigate the efficacy of exenatide and insulin glargine in patients with newly diagnosed type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD).
    Summary · context
    We performed a 24-week randomized controlled multicentre clinical trial.
    Summary · context
    Seventy-six patients were randomly assigned 1:1 to receive exenatide or insulin glargine treatment.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes and fatty liver disease, exenatide reduced LDL cholesterol more than insulin glargine.

    In plain wordsIn patients with diabetes and fatty liver disease, exenatide reduced LDL cholesterol more than insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseLDL cholesterol
    Study

    n = 76

    Comparator
    Insulin glargine
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    The body weight, waist circumference, postprandial plasma glucose, and low-density lipoprotein cholesterol (LDL-C) in the exenatide group also presented greater reductions than the insulin glargine group (P < .05).
    3 context sentences
    Summary · context
    The aim of this study was to investigate the efficacy of exenatide and insulin glargine in patients with newly diagnosed type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD).
    Summary · context
    We performed a 24-week randomized controlled multicentre clinical trial.
    Summary · context
    Seventy-six patients were randomly assigned 1:1 to receive exenatide or insulin glargine treatment.
  8. 08HumanRandomized controlled trialSafety outcome

    In patients with diabetes and fatty liver disease, adverse event proportions were comparable with exenatide and insulin glargine.

    In plain wordsIn patients with diabetes and fatty liver disease, adverse event proportions were similar with exenatide and insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeAdverse event proportion
    Study

    n = 76

    Comparator
    Insulin glargine
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    The proportion of adverse events were comparable between the two groups.
    3 context sentences
    Summary · context
    The aim of this study was to investigate the efficacy of exenatide and insulin glargine in patients with newly diagnosed type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD).
    Summary · context
    We performed a 24-week randomized controlled multicentre clinical trial.
    Summary · context
    Seventy-six patients were randomly assigned 1:1 to receive exenatide or insulin glargine treatment.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes and fatty liver disease, visceral adipose tissue decreased after exenatide treatment.

    In plain wordsIn patients with diabetes and fatty liver disease, fat around internal organs decreased during exenatide treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseVisceral adipose tissue
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    Visceral adipose tissue change
    −43.57 cm2
    exenatide

    Source sentences

    Summary
    LFC, VAT, SAT, and FIB-4 were significantly reduced after exenatide treatment (ΔLFC, -17.55 ± 12.93%; ΔVAT, -43.57 ± 68.20 cm2 ; ΔSAT, -28.44 ± 51.48 cm2 ; ΔFIB-4, -0.10 ± 0.26; all P < .05).
    3 context sentences
    Summary · context
    The aim of this study was to investigate the efficacy of exenatide and insulin glargine in patients with newly diagnosed type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD).
    Summary · context
    We performed a 24-week randomized controlled multicentre clinical trial.
    Summary · context
    Seventy-six patients were randomly assigned 1:1 to receive exenatide or insulin glargine treatment.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes and fatty liver disease, subcutaneous adipose tissue decreased after exenatide treatment.

    In plain wordsIn patients with diabetes and fatty liver disease, fat beneath the skin decreased during exenatide treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseSubcutaneous adipose tissue
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    Subcutaneous adipose tissue change
    −28.44 cm2
    exenatide

    Source sentences

    Summary
    LFC, VAT, SAT, and FIB-4 were significantly reduced after exenatide treatment (ΔLFC, -17.55 ± 12.93%; ΔVAT, -43.57 ± 68.20 cm2 ; ΔSAT, -28.44 ± 51.48 cm2 ; ΔFIB-4, -0.10 ± 0.26; all P < .05).
    3 context sentences
    Summary · context
    The aim of this study was to investigate the efficacy of exenatide and insulin glargine in patients with newly diagnosed type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD).
    Summary · context
    We performed a 24-week randomized controlled multicentre clinical trial.
    Summary · context
    Seventy-six patients were randomly assigned 1:1 to receive exenatide or insulin glargine treatment.
  11. 11HumanRandomized controlled trialEfficacy outcome

    In patients with diabetes and fatty liver disease, FIB-4 decreased after exenatide treatment.

    In plain wordsIn patients with diabetes and fatty liver disease, a liver fibrosis index decreased during exenatide treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseFibrosis-4 index
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 24 weeksAs given in this study (human).

    Measurements

    FIB-4 change
    −0.1 index
    exenatide

    Source sentences

    Summary
    LFC, VAT, SAT, and FIB-4 were significantly reduced after exenatide treatment (ΔLFC, -17.55 ± 12.93%; ΔVAT, -43.57 ± 68.20 cm2 ; ΔSAT, -28.44 ± 51.48 cm2 ; ΔFIB-4, -0.10 ± 0.26; all P < .05).
    3 context sentences
    Summary · context
    The aim of this study was to investigate the efficacy of exenatide and insulin glargine in patients with newly diagnosed type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD).
    Summary · context
    We performed a 24-week randomized controlled multicentre clinical trial.
    Summary · context
    Seventy-six patients were randomly assigned 1:1 to receive exenatide or insulin glargine treatment.

Studies that did not test the peptide alone1

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 12HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome

    Liver fat decreased after exenatide treatment in patients with diabetes and fatty liver disease. The summary also reports a decrease after insulin glargine.

    In plain wordsLiver fat decreased after exenatide and after insulin glargine. This result does not isolate an exenatide effect.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseLiver fat content
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Liver fat and liver function · Liver

    Measurements

    Liver fat change
    −17.55%
    exenatide

    Source sentences

    Summary
    LFC, VAT, SAT, and FIB-4 were significantly reduced after exenatide treatment (ΔLFC, -17.55 ± 12.93%; ΔVAT, -43.57 ± 68.20 cm2 ; ΔSAT, -28.44 ± 51.48 cm2 ; ΔFIB-4, -0.10 ± 0.26; all P < .05).
    4 context sentences
    Summary · context
    The aim of this study was to investigate the efficacy of exenatide and insulin glargine in patients with newly diagnosed type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD).
    Summary · context
    We performed a 24-week randomized controlled multicentre clinical trial.
    Summary · context
    Seventy-six patients were randomly assigned 1:1 to receive exenatide or insulin glargine treatment.
    Summary · context
    Both exenatide and insulin glargine reduced LFC in patients with drug-naive T2DM and NAFLD; however, exenatide showed greater reductions in body weight, visceral fat area, liver enzymes, FIB-4, postprandial plasma glucose, and LDL-C.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.